BRAF and lung cancer: All of the clinically-relevant variants of the EGFR, ALK, BRAF and KRAS genes are unambiguously lung cancer-associated and do not meet CHIP criteria; therefore, the presence of CHIP-associated variants doesn’t affect clinical decision making.